secukinumab,tofacitinib,risankizumab,etanercept,abatacept,certolizumab,ixekizumab,adalimumab,infliximab,upadacitinib,ustekinumab,bimekizumab,guselkumab,golimumab,apremilast
ucb pharmaceuticals,novartis,janssen,eli lilly,abbvie,bms,amgen,pfizer,boehringer ingelheim
['upadacitinib', 'etanercept', 'sarilumab', 'adalimumab', 'tofacitinib', 'netakimab', 'risan', 'brodalumab', 'ixekizumab', 'golimumab', 'ustekinumab', 'tocilizumab', 'rituximab', 'toci', 'secukinumab', 'abatacept', 'infliximab', 'tofa', 'certolizumab', 'bimekizumab', 'ritux', 'axspa']
current treatment recommendations for axial spondyloarthritis + levels of evidence
+ disease manifestations pr. d sir e van der heijde
#eular2023
#spondyloarthritis
nz 
Annals of the Rheumatic Diseases (#1 research journal in Rheumatology) & RMD Open are the official @EULAR_ORG journals. High quality, peer reviewed research.